(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/238790 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2024/029687

(22) International Filing Date:
16 May 2024 (16.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/467,208 17 May 2023 (17.05.2023) US

(71) Applicant: **ODYSSEY THERAPEUTICS, INC.** [US/US]; 51 Sleeper Street, Suite 800, Boston, MA 02210 (US).

(72) Inventors: **HUBER, Ferdinand**; Industriepark Höchst, G875, 65926 Frankfurt am Main (DE). **PREISS, Laura**; Industriepark Höchst, G875, 65926 Frankfurt am Main (DE). **SEIFRIED, Annegrit**; Industriepark Höchst, G875, 65926 Frankfurt am Main (DE). **STUWE, Tobias**; Industriepark Höchst, G875, 65926 Frankfurt am Main (DE).

(74) Agent: **CHEN, Hongfan** et al.; Troutman Pepper Hamilton Sanders LLP, 875 Third Avenue, New York, NY 10022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MODIFIED SINGLE-DOMAIN ANTIBODIES

(57) Abstract: The present disclosure provides single-domain antibodies comprising one or more modifications, e.g., at the carboxy-terminus (C-terminus), which can reduce binding by anti-drug antibodies to the carboxy-terminus of the single-domain antibodies as compared to an unmodified single-domain antibody. The application also provides fusion proteins and conjugates comprising the single-domain antibodies, polynucleotides and recombinant vectors encoding the single-domain antibodies, compositions and kits comprising same, as well as host cells and methods for preparing the single-domain antibodies.

WO 2024/238790 A1